Why the study?
The authors aimed to analyse and update knowledge on the management of heart failure with preserved ejection fraction.
Answers are grounded in this paper and cite their sources.
This review summarizes current evidence and guidelines for HFpEF, highlighting SGLT2 inhibitors as the primary evidence-based disease-modifying therapy.
BACKGROUND: Heart failure (HF) is a complex clinical syndrome that results when heart’s ability to contract or fill is impaired structurally or functionally. Current guideline has been classified HF according to level of left ventricular ejection fraction (EF). 1) Heart failure with reduced ejection fraction (HRrEF): EF ≤ 40%; 2) Heart failure with mildy ejection fraction (HRmrEF): EF 41 - 49%; 3) Heart failure with preserved ejection fraction (HRpEF): EF ≥50%. AIM: We aimed to analyse the management of heart failure with preserved ejection fraction. METHODS: We conducted a literature search of relevant articles in various databases (Pubmed & Google Scholar). Articles to include in the review was based on agreement of the authors. RESULTS: Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of all heart failure cases. HFpEF remains a challenging condition to diagnose given its unclear and often heterogenous etiology with numerous clinical mimics and complex systemic pathophysiology. CONCLUSION: Additionally, effective treatment modalities are limited with numerous negative clinical trials over the past few decades. In this review, we updated the last knowledge of management HFpEF by reviewing recent guideline and studies.
No takes yet. Share an insight, caveat, or question.
Laksono et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: